Published in Br J Haematol on November 19, 2008
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets (2011) 2.58
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica (2013) 1.76
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia (2009) 1.68
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood (2014) 1.56
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica (2013) 1.03
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia (2013) 0.97
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica (2014) 0.95
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J (2013) 0.93
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood (2014) 0.91
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol (2010) 0.89
Treatment of relapsed and refractory multiple myeloma. Haematologica (2016) 0.83
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia (2015) 0.83
Development of target-specific treatments in multiple myeloma. Br J Haematol (2010) 0.83
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol (2013) 0.81
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer (2015) 0.79
Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematology Am Soc Hematol Educ Program (2010) 0.78
Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer J (2013) 0.78
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response. Blood Cancer J (2016) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Successful treatment of primary advanced gastric plasmacytoma using a combination of surgical resection and chemotherapy with bortezomib: A case report. Int J Surg Case Rep (2016) 0.75
Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients. Adv Ther (2014) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol (2009) 3.14
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol (2012) 2.94
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med (2005) 2.67
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 2.44
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma (2007) 2.41
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood (2002) 2.38
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood (2008) 2.25
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood (2007) 2.20
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res (2009) 2.17
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood (2012) 2.07
Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer (2003) 2.06
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res (2008) 1.94
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica (2005) 1.92
Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol (2012) 1.90
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 1.88
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood (2012) 1.88
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood (2013) 1.84
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood (2004) 1.82
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood (2005) 1.81
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood (2011) 1.76
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
A molecular compendium of genes expressed in multiple myeloma. Blood (2002) 1.70
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood (2011) 1.69
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood (2011) 1.69
Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients. Regen Med (2013) 1.68
Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer (2011) 1.67
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res (2007) 1.66
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood (2009) 1.65
Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood (2009) 1.63
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs (2007) 1.60
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma (2011) 1.60
Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood (2003) 1.58
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood (2013) 1.57
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56
Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res (2005) 1.56
Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis (2004) 1.55
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol (2009) 1.54
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma (2007) 1.54
Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet (2005) 1.53